Pharmaceutical company Moderna says that the first dose of its CCP virus vaccine has been given to children aged six months to 11 years in a trial called the KidCOVE study. “This pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population,” said Moderna CEO Stéphane Bancel in a press release on Monday. The trial—conducted in collaboration with the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority—plans to enroll around 6,750 children in the United States and Canada to test the effectiveness and safety of the mRNA-1273 vaccine that is being given to adults around the world. The Moderna vaccine is only authorized for use in adults 18 and older. But that may change as the company has begun testing its vaccine in the adolescent population aged 12 to 17, with the …